Why in the News?
The Ministry of Science & Technology has launched Nafithromycin, India’s first indigenous antibiotic to combat drug-resistant infections.
About Nafithromycin:
| Details | |
| About | • It was developed with the support of the Biotechnology Industry Research Assistance Council (BIRAC), a unit under the Department of Biotechnology, to combat antimicrobial resistance (AMR). • It aims to treat Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria. ( Awaiting final approval from CDSCO for manufacturing and public use.) |
| Features | • Developed over 14 years of clinical trials in the U.S., Europe, and India. • 10 times more effective than azithromycin. (3 doses to combat Drug-Resistant Pneumonia) • Minimal side effects, no significant drug interactions, and food-independent. |
| Significance | • It targets both typical and atypical pathogens. • It addresses a global health issue, especially CABP, contributing to over 2 million deaths annually. • Offers a more effective, faster, and safer treatment for drug-resistant pneumonia. • Demonstrates successful public-private collaboration between the government and Wockhardt Pharmaceuticals. • A cost-effective solution for treating resistant infections in low-resource settings. |
PYQ:[2019] Which of the following are the reasons for the occurrence of multi-drug resistance in microbial pathogens in India?
Select the correct answer using the code given below. (a) 1 and 2 |
